Simple Summary Peptide receptor radionuclide therapy (PRRT) is one of the treatment
options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine …

This ENETS guidance paper for well‐differentiated nonfunctioning pancreatic
neuroendocrine tumours (NF‐Pan‐NET) has been developed by a multidisciplinary working …

According to the 2019 WHO pathology grading system, high-grade gastroenteropancreatic
neuroendocrine neoplasms (GEP-NENs) can be divided into well differentiated …

There is no standardized treatment for grade 3 neuroendocrine tumors (G3 NETs). We
aimed to describe the treatments received in patients with advanced G3 NETs and compare …

Background In advanced neuroendocrine tumors (NET), antiproliferative treatment options
beyond somatostatin analogs remain limited. Temozolomide (TMZ) has shown efficacy in …

The NETTER-2 trial provides the first phase III evidence that 177Lu-dotatate is active as first-
line therapy in patients with gastroenteropancreatic neuroendocrine tumours with a Ki-67 …

Background There are currently no standard first-line treatment options for patients with
higher grade 2–3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine …

Purpose This paper outlines the consensus of the Italian Association for Neuroendocrine
Tumors (Itanet), the Italian Association of Nuclear Medicine (AIMN), the Italian Society of …

Abstract Background Grade 1/2 PanNETs are mostly managed similarly, typically without
any adjunct treatment with the belief that their overall metastasis rate is low. In oncology …

Small intestinal neuroendocrine tumours (Si-NET) are often studied as a uniform group.
Proliferation index Ki-67 influences prognosis and determines tumour grade. We …